ASMB — ASSEMBLY BIOSCIENCES, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1426800 ·
Last close
$22.50
Market Cap
$460.74M
52W High
$39.71
52W Low
$19.20
ADV30
250,083
Next earnings
—
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,956,000 — -23,415,000 -20,256,000 325,286,000 29,073,000 26,493,000
Jun 2026 13,374,000 — -6,344,000 -3,857,000 330,832,000 32,286,000 25,183,000
Mar 2026 8,213,000 — -11,370,000 -9,079,000 235,508,000 31,120,000 36,898,000
Dec 2025 42,469,000 — 19,799,000 22,090,000 257,590,000 58,450,000 50,839,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-38,481,000
Investing CF
$-234,511,000
Financing CF
$281,272,000
CapEx
$-43,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.79
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-844,983,000
Inventory
—
Receivables
$822,000
ST Investments
$288,075,000
EBIT TTM
$-8,798,000
Pretax Income TTM
$-42,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$67,012,000
EBITDA
$-21,228,000
Free Cash Flow
$-36,266,248
Enterprise Value
$120,424,392
Total Cash
$314,262,016
Total Debt
$2,207,000
Shares Out
20,477,244
Trailing EPS
$0.75
Book Value
$14.67
ROE
-4.6%
ROA
-4.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 72,303,000 -12,118,000 -6,122,000 257,590,000 50,839,000 206,751,000 -41,093,000
Dec 2024 28,520,000 -45,420,000 -40,177,000 119,168,000 85,809,000 33,359,000 -51,117,000
Dec 2023 7,163,000 -64,646,000 -61,228,000 136,823,000 95,726,000 41,097,000 22,743,000
Dec 2022 0 -94,114,000 -93,092,000 101,794,000 19,130,000 82,664,000 -84,463,000

TTM Snapshot

Revenues TTM
$74,845,000
NetIncome TTM
$-42,000
OpCashFlow TTM
—
Assets (Latest)
$330,832,000
Forward EPS
$-2.57

Max Pain — expiry 2026-12-18

max pain strike: $15.00 · spot: $22.39 · call oi: 1,084 · put oi: 170
Expected Move to 2026-12-18: ±$4.20 (18.76%) — implied range $18.19 – $26.59 · ATM straddle on $22.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AQST Aquestive Therapeutics, Inc. $465.04M $3.70 —
STTK Shattuck Labs, Inc. $467.46M $4.59 —
DMAC DiaMedica Therapeutics Inc. $452.16M $8.38 —
KMDA KAMADA LTD $470.92M $8.16 —
AMRN AMARIN CORP PLC\UK $473.82M $11.27 —

News headlines (Yahoo Finance, 1h cache)

Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:15 · Yahoo
Assembly Biosciences: Q3 Earnings Snapshot
2026-11-12 21:10 · Yahoo
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
2026-11-12 21:00 · Yahoo
Assembly Biosciences to Participate in Upcoming Investor Conferences
2026-11-02 21:00 · Yahoo
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
2026-10-29 20:00 · Yahoo
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
2026-10-05 14:00 · Yahoo
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
2026-09-10 20:15 · Yahoo
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
2026-09-08 13:48 · Yahoo
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
2026-09-07 13:55 · Yahoo
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
2026-09-04 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.